Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer

被引：0
|
作者：
Qifei He
Jiahui Chen
Kai Zhou
Chenggen Jin
Anqiang Wang
Ke Ji
Xin Ji
Ji Zhang
Xiaojiang Wu
Xia Li
Zhaode Bu
Jiafu Ji
机构：
[1] Peking University Cancer Hospital and Institute,Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Karolinska Institutet,Department of Medical Epidemiology and Biostatistics
来源：
Annals of Surgical Oncology | 2021年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4413 / 4422
页数：9
相关论文
共 50 条
  • [1] Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer
    He, Qifei
    Chen, Jiahui
    Zhou, Kai
    Jin, Chenggen
    Wang, Anqiang
    Ji, Ke
    Ji, Xin
    Zhang, Ji
    Wu, Xiaojiang
    Li, Xia
    Bu, Zhaode
    Ji, Jiafu
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) : 4413 - 4422
  • [2] Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer
    Murthy, Rashmi K.
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana
    Murray, James L.
    Koenig, Kimberly H.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Giordano, Sharon H.
    Booser, Daniel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    CANCER, 2014, 120 (13) : 1932 - 1938
  • [3] Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
    Kotani, Daisuke
    Shitara, Kohei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [4] Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer
    Mishima, Saori
    Shitara, Kohei
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 825 - 830
  • [5] Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
    Harbeck, Nadia
    BREAST, 2022, 62 : S12 - S16
  • [6] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [7] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [8] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    LANCET, 2005, 366 (9486): : 634 - 634
  • [9] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
    Croxtall, Jamie D.
    McKeage, Kate
    DRUGS, 2010, 70 (17) : 2259 - 2267
  • [10] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
12345